% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Feuerecker:275422,
      author       = {B. Feuerecker$^*$ and C. Kratochwil and H. Ahmadzadehfar
                      and A. Morgenstern and M. Eiber and K. Herrmann$^*$ and K.
                      L. Pomykala},
      title        = {{C}linical {T}ranslation of {T}argeted α-{T}herapy: {A}n
                      {E}volution or a {R}evolution?},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {5},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-00745},
      pages        = {685-692},
      year         = {2023},
      note         = {2023 May;64(5):685-692},
      abstract     = {The field of radioligand therapy has advanced greatly in
                      recent years, driven largely by β-emitting therapies
                      targeting somatostatin receptor-expressing tumors and the
                      prostate-specific membrane antigen. Now, more clinical
                      trials are under way to evaluate α-emitting targeted
                      therapies as potential next-generation theranostics with
                      even higher efficacy due to their high linear energy and
                      short range in human tissues. In this review, we summarize
                      the important studies ranging from the first Food and Drug
                      Administration-approved α-therapy, 223Ra-dichloride, for
                      treatment of bone metastases in castration-resistant
                      prostate cancer, including concepts in clinical translation
                      such as targeted α-peptide receptor radiotherapy and
                      225Ac-PSMA-617 for treatment of prostate cancer, innovative
                      therapeutic models evaluating new targets, and combination
                      therapies. Targeted α-therapy is one of the most promising
                      fields in novel targeted cancer therapy, with several early-
                      and late-stage clinical trials for neuroendocrine tumors and
                      metastatic prostate cancer already in progress, along with
                      significant interest and investment in additional
                      early-phase studies. Together, these studies will help us
                      understand the short- and long-term toxicity of targeted
                      α-therapy and potentially identify suitable therapeutic
                      combination partners.},
      subtyp        = {Review Article},
      keywords     = {225Ac (Other) / PSMA-617 (Other) / targeted α-therapy
                      (Other) / α-emitter (Other)},
      cin          = {MU01 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37055224},
      doi          = {10.2967/jnumed.122.265353},
      url          = {https://inrepo02.dkfz.de/record/275422},
}